View printer-friendly version
<< Back
CytomX Highlights Data from Multiple Probody Pipeline Programs at Investor Event During AACR-NCI-EORTC Conference
CytomX Reviews Preclinical Proof-of-Concept Study for PD-L1 Program, Lead Candidate CX-072
First Data for CD166 Probody Drug Conjugate Program and T-cell Engaging Probody Bispecifics Program Presented During Poster Session

BOSTON, Nov. 8, 2015 /PRNewswire/ -- CytomX Therapeutics (Nasdaq: CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, highlighted data during an investor event today that demonstrate how its Probody technology improves targeting to create safer and more effective therapies across multiple pipeline programs.

Posters containing the data can be found on the Publications page of CytomX's website. A replay of the investor event will be posted on the Investors and News page of CytomX's website at 8 p.m. EST today and will be available for 60 days.

"Our research team has demonstrated preclinical proof-of-concept for our Probody technology across a number of our pipeline programs. We have consistently shown the ability of the platform to create safer and more effective therapies across multiple antibody modalities in cancer," said Michael Kavanaugh, M.D., chief scientific officer of CytomX. "Based on these findings, we have moved CX-072 and our CD166 programs into IND-enabling work. In addition, our T-cell engaging bispecific data illustrate the potential of this promising modality."

CytomX discussed preclinical results from its lead program CX-072, a PD-L1-directed Probody therapeutic, that were initially presented at the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference on September 16. In addition, the company presented data from its Probody drug conjugate program directed against CD166, as well as on its proprietary T cell-engaging Probody bispecific platform, that were presented this week in poster sessions at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

Therapeutics developed with CytomX's Probody platform are designed to be active in the tumor while sparing healthy tissue. By restricting activity to the tumor microenvironment, Probody therapeutics directed against both validated and novel targets enable anti-tumor efficacy with a significantly enhanced safety window, relative to traditional antibody-based therapies. CytomX's preclinical pipeline of wholly-owned and partnered programs includes Probody cancer immunotherapies, Probody drug conjugates and T-cell engaging Probody bispecifics.

About CytomX Therapeutics 
CytomX is an oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody technology platform. The company uses the platform to create development-stage proprietary cancer immunotherapies against clinically-validated targets, as well as to develop first-in-class investigational cancer therapeutics against novel targets. CytomX believes that its Probody platform has the potential to improve the combined efficacy and safety profile of monoclonal antibody modalities, including cancer immunotherapies, antibody drug conjugates and T-cell-recruiting bispecific antibodies. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. Investigational Probody therapeutics are being developed that address clinically-validated cancer targets in immuno-oncology, such as PD-L1 against which our clinical candidate CX-072 is directed, as well as novel targets, such as CD-166, that are difficult to drug without causing damage to healthy tissues, or toxicities. In addition to its proprietary programs, CytomX is collaborating with strategic partners including Bristol-Myers Squibb Company, Pfizer Inc., MD Anderson Cancer Center and ImmunoGen, Inc. For more information, visit

Forward-Looking Statements 
This press release includes forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that are difficult to predict, may be beyond our control, and may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied in such statements. Accordingly, you should not rely on any of these forward-looking statements. Our Probody platform is in preclinical development, and the process by which a preclinical technology could potentially lead to an approved product is long and subject to significant risks and uncertainties. Applicable risks and uncertainties include those relating to our preclinical research and development and other risks identified under the heading "Risk Factors" included in our filings with the SEC. The forward-looking statements contained in this press release are based on information currently available to CytomX and speak only as of the date on which they are made. CytomX does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise.

Media Contacts:  
Canale Communications 
Ian Stone 

Investor Contacts: 
Trout Group 
Pete Rahmer 

CytomX Therapeutics is developing a pipeline of Probody(TM) therapeutics for cancer.

Logo -

To view the original version on PR Newswire, visit:

SOURCE CytomX Therapeutics